Sekisui Diagnostics (SDG) announced today that BioMedica Diagnostics (BMD) will acquire certain assets associated with its specialty coagulation business, under an asset transfer agreement. Located in Nova Scotia, Canada, BMD is a diagnostic company which develops and manufactures a comprehensive line of coagulation products. The agreement includes all expertise and ongoing business associated with specialty coagulation worldwide, with the exception of Europe, Middle East and Africa, where SDGmbH, a Sekisui Diagnostics subsidiary, will continue to distribute and support the products in partnership with BMD. BMD will also acquire the American Diagnostica trademark, which is part of this business, and looks forward to reintroducing the brand, building on the long-standing reputation of this product line.

The transaction will close and BMD will operate the business as of December 1st, 2016.

As a diagnostics company with a focus on providing customized diagnostic solutions in human and animal health, BMD develops and manufactures a comprehensive line of reagents, kits, calibrators and controls for use both in routine and specialty coagulation and also partners with global organizations to develop customized, new-to-world coagulation reagent technologies.

BMD will continue to meet all customer needs and the current levels of exceptional service and support, and no interruption in business is anticipated.

Coagulation products are, and will continue to be, a focus area for Sekisui Diagnostics in the IVD segment through automated coagulation testing. We thank all our customers for their business and loyalty to the specialty coagulation product line over the years.

For more information or to purchase products from BMD call Nadine Williams at 1-902-798-0982 or email [email protected]

For any inquiries related to automated coagulation or other Sekisui Diagnostics’ products and services, please contact Lisa Williams at 1-858-777-2660 or email [email protected]